Jim Simons
LYEL icon

Jim Simons’s Lyell Immunopharma LYEL Stock Holding History

Jim Simons’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Buy
130,190
+13,779
+12% +$249K ﹤0.01% 2008
2026
Q1 		$2.34M Buy
116,411
+76,921
+195% +$1.8M ﹤0.01% 1818
2025
Q4 		$1.22M Sell
39,490
-24,500
-38% -$548K ﹤0.01% 2174
2025
Q3 		$1.04M Sell
63,990
-3,200
-5% -$36.5K ﹤0.01% 2461
2025
Q2 		$594K Sell
67,190
-21,235
-24% -$194K ﹤0.01% 2753
2025
Q1 		$951K Buy
88,425
+7,818
+10% +$95.8K ﹤0.01% 2457
2024
Q4 		$1.03M Buy
80,607
+70,737
+717% +$1.4M ﹤0.01% 2482
2024
Q3 		$272K Buy
9,870
+2,255
+30% +$66.3K ﹤0.01% 3010
2024
Q2 		$221K Sell
7,615
-13,560
-64% -$646K ﹤0.01% 3011
2024
Q1 		$944K Buy
21,175
+17,550
+484% +$751K ﹤0.01% 2523
2023
Q4 		$141K Buy
+3,625
New +$131K ﹤0.01% 3226
2022
Q4 		– Sell
-2,035
Closed -$298K – 4280
2022
Q3 		$298K Sell
2,035
-475
-19% -$64.3K ﹤0.01% 3216
2022
Q2 		$327K Sell
2,510
-165
-6% -$16.9K ﹤0.01% 3404
2022
Q1 		$270K Buy
+2,675
New +$324K ﹤0.01% 3515

Other funds holding LYEL

Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GSK plc
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Decheng Capital
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Almitas Capital
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Foresite Capital Management V
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Jim Simons's LYEL Position: Q2 2026 in Review

Jim Simons increased its Lyell Immunopharma (LYEL) stake by 12% in Q2 2026, buying an estimated $249K and bringing the position to 130,190 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2008.

Jim Simons first reported a position in LYEL in Q1 2022 and has held it in 14 quarters since. The position peaked at $2.34M in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Jim Simons held 130,190 shares of Lyell Immunopharma worth $1.83M as of Q2 2026.
  • Jim Simons bought 13,779 Lyell Immunopharma shares in Q2 2026, an estimated $249K.
  • Lyell Immunopharma made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2008 holding.
  • Jim Simons first reported a position in Lyell Immunopharma in Q1 2022 and has held it in 14 quarters since.
  • Jim Simons's Lyell Immunopharma position peaked at $2.34M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.